Skip to main content

FMS · Fresenius Medical Care AG

Track FMS — free
$20.44 +0.31 (+1.54%) At close · Nov 20
Market Cap
$10.61B
Shares
519.02M
Volume · Nov 20 1.34M Avg daily vol (3M) 1.17M

Price & Indicators

 

Key stats

Close
$20.44
Fri 20 Nov
Open
$20.49
Fri 20 Nov
Average volume, 30 days
1.6M
shares a session
Short interest
3.0M
0.6% of shares · 2.2 days to cover
Day range
$20.38$20.72
Open $20.49 Close $20.44
52-week closing range
$20.13$25.70
Close $20.44 20.5% under the high
Short volume, last session
50%
Last earnings
Nov 3, 2026
Price history
Jan 2020 to Nov 2026

Up next

Feb 23, 2027 Scheduled · in 13 wks

Latest documents

2026
Nov 9
Current report 6-K
€500 million bond placed with 4.250% coupon

Fresenius Medical Care placed a €500 million bond maturing in February 2032, with a 4.250% p.a. coupon and 4.363% p.a. yield. Proceeds will fund general corporate purposes, including refinancing existing financial liabilities; settlement is envisaged for November 16, 2026.

4 source passages
Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, today successfully placed a bond with a volume of €500 million. The bond maturing in February 2032 and a coupon of 4.250% p.a. was issued at a price of 99.497% resulting in a yield of 4.363% p.a. The proceeds will be used for general corporate purposes, including the refinancing of existing financial liabilities. The envisaged settlement date is November 16, 2026. Open the document at this passage
Nov 3
Earnings call
Outlook lowered amid reimbursement headwinds

Fresenius Medical Care lowered its 2026 operating income outlook to between flat and a negative mid-single-digit percentage and expects total headwinds of 300 to 350 million in 2027 from reimbursement-related and base-business pressures.

4 source passages
I'm very pleased to be here and to be speaking with you for the first time as the CEO of Fresenius Medical Care. we are narrowing our outlook for 2026. We're moving to the lower half of our prior guidance. We now expect operating income growth to be between flat and a negative mid-single-digit percentage birth rate compared to prior year. Looking beyond the current year, I recognize there is a considerable interest In how we see our business developing in 2027. we do expect pressure on the base business also in addition to the DARPA tailwind that we had, and that is kind of leading up to a total of 300 to 350 million of headwinds in 27 against our 26 number, to be very precise. Open the document at this passage
Nov 3
Current report 6-K
CMS boosts 2027 dialysis payments by 2.7%

Fresenius Medical Care AG said CMS’s final 2027 ESRD PPS sets the base rate at $297.52, up $15.81 from $281.71, and projects 2.7% higher aggregate payments to all ESRD facilities.

Read from the first part of this long document
2 source passages
FRESENIUS MEDICAL CARE AG On October 28, 2026, CMS issued a final rule for the 2027 ESRD PPS, which CMS projects will increase the total aggregate payments to all ESRD facilities by 2.7%. For calendar year (CY) 2027, the ESRD PPS base rate is $297.52, an increase of $15.81 from the CY 2026 base rate of $281.71. Open the document at this passage
Nov 3
Current report 6-K
Profit falls as full-year operating-income outlook narrows

Fresenius Medical Care reported third-quarter revenue of EUR 4,937 million, operating income of EUR 384 million, down 19%, and net income of EUR 160 million, down 42%. It narrowed its 2026 operating-income outlook to between flat and a negative mid-single digit percent growth rate.

5 source passages
**Fresenius Medical Care reports third quarter 2026 performance partially offsetting headwinds and narrowing full year outlook** In the **third quarter of 2026, Group** revenue increased by 1% compared to prior year (-1% at constant currency, +0.1% organic^1^) to EUR 4,937 million. In the **third quarter of 2026, Group** operating income declined by 19% (-19% at constant currency) to EUR 384 million, resulting in a margin of 7.8% (Q3 2025: 9.8%). **Net income^3^** decreased by 42% compared to prior year (-41% at constant currency) to EUR 160 million in the **third quarter of 2026**. Fresenius Medical Care continues to expect **revenue growth^1^** to be broadly flat in 2026 compared to prior year. The company narrows its outlook for **operating income^2^** and now expects **operating income^2^** growth to be between flat and a negative mid-single digit percent growth rate compared to prior year. Open the document at this passage
Oct 7
Current report 6-K
Current report

Fresenius Medical Care AG appointed Shervin J. Korangy CEO and Chair of the Management Board effective October 12, 2026, succeeding Helen Giza; he resigned from the Supervisory Board, and Ann Custin was identified as his successor.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$22.63B
Trailing 12 months
Net income (TTM)
$956.14M
Trailing 12 months
Revenue growth YoY
+1.1%
Year over year
Operating margin
8.9%
Trailing 12 months
P / E (TTM)
11.1
Trailing earnings · reciprocal yield 9.0%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
4.3%
Trailing 12 months
Shares change YoY
-4.8%
Year over year · fewer shares
Price change (1Y)
-9.5%
Trailing year
Short interest
0.6%
Latest settlement · 2.2 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Strong Sell Momentum Weak Sentiment Neutral Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 35.9 · fear Equity put/call 0.77
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −11%
below
Price vs 50-day avg −8%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 6%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −10%
trailing
6-month return −1%
trailing
YTD return −14%
this year
Relative strength +9%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $22 › 200d $23 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.58% of shares out · ▼ -24.0% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
232 holders — mid 3-yr range
Squeeze score 42
elevated · 0–100
Fundamentals
Strong
Revenue growth +6%
Y/Y
Gross margin 110%
expanding
EPS growth +20%
Y/Y
Free cash flow $1.1B
Balance sheet $7.1B
net debt
Quant / Vol
risk profile
Moderate
Volatility 31%
annualized · 1-yr
Max drawdown −22%
past year
ATR 3.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 4, 2026
Converting our machines in our own clinics · 2026 20%
Previous outlook earlier release · from the Earnings Call filed Aug 5, 2025

Still-open targets the latest release did not restate under the same label.

U.S. CD EBIT · 2026 2%
Prior guidance period ended · from the Earnings Call filed Aug 4, 2026
3 to 7 percent CAGA growth assumption · 2025 base 3% – 7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−11% Bearish
Price vs 50-day avg
−8% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
6% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $22 › 200d $23 — 200d above 50d
Institutional flow Distributing
-3% holders QoQ · +29 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.58% of shares out · ▼ -24.0% MoM · 2.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
232 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $20 Now $20 · 6% Range high $26
vs 200-day avg -11% vs 50-day avg -8%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Medical Care Facilities — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
FMS
Fresenius Medical Care AG
this stock
$10.61B -14.2% +5.9% — 0.6%
HCA
HCA Healthcare, Inc.
$99.34B +1.9% +7.1% 15.8 2.3%
FSNUY
Fresenius SE & Co. KGaA
$31.59B -2.2% — — 0.0%
THC
Tenet Healthcare Corp
$20.95B +32.4% +0.9% 7.6 2.2%
EHC
Encompass Health Corp
$13.11B +25.9% +10.5% 20.9 3.7%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
232
% held
8.0%
Net QoQ
-947.9K sh
Top holder
PZENA INVESTMENT MANAGEME…
Held Float
View
Held by Funds
Fund positions
23
View
Short & Settlement
Short Interest Falling
Shares short
3.0M
Days to cover
2.2d
Change
-948.9K sh
View
Short Volume
Short vol %
50%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
8.7K
Value
$196.9K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
27.0%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 30, 2026
View
Financials
Financials
Revenue (FY)
$5.3B
Net income (FY)
$1.2B
EPS diluted
$4.06
View
Filings
SEC Filings
Latest
6-K
Filed
Nov 9, 2026
This year
20

Fresenius Medical Care placed a €500 million bond maturing in February 2032, with a 4.250% p.a. coupon and 4.363% p.a. yield. Proceeds will fund general corporate purposes, including refinancing existing financial liabilities; settlement is envisaged for November 16, 2026.

View
Proposed Sales
Value
$119.2K
Shares
5.7K
Filed
Dec 20, 2023
View
Earnings & Events
Webcasts Upcoming
Next webcast
Feb 23, 2027
Last webcast
Nov 3, 2026
View
Investor Relations
Upcoming events
9
View

Performance

5D 20D 120D MTD YTD
FMS -7.2% -9.9% -0.5% -9.0% -14.2%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY +1.3% -0.7% +8.6% -0.3% -15.4%

Capital returns

Latest dividend
$0.872 / share · ex May 22, 2026
Raised 7%
Paid (TTM)
$0.872 / share · 1 payout
Dividend yield (TTM, derived)
— · history filling in
Full dividend history

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1333141 CUSIP 358029106 13F (30d) 227 filings 192 filers Visit website Investor relations